Search

everythinglearnresearchcommunity

for

Search:↓

Baricitinib is effective for severe alopecia areata with manageable side effects, mainly upper respiratory infections.

The document warns against US clinics selling untested stem cell treatments without FDA approval.

Hormone treatments can help with women's skin and hair disorders, but they need careful monitoring and more research.

Finasteride and minoxidil are effective FDA-approved treatments for androgenetic alopecia.

Exosomes could improve skin and hair treatments, but more research and regulation are needed.

New treatments for hair loss are emerging, and doctors need to learn how to use them effectively.

Dutasteride is effective for treating prostate enlargement and reducing related surgery risk, but is not approved for preventing prostate cancer.

Taking biotin supplements can be risky and often lacks evidence of effectiveness for skin, hair, and nail issues.

Upadacitinib effectively treats skin conditions like eczema and psoriasis and is becoming more widely used and affordable.

Oral minoxidil is an effective alternative for hair loss but may cause more unwanted hair growth.

Lasers are FDA-approved for permanent hair reduction, not removal, and more research is needed to improve treatments.

Restolin Hair Supplement may help hair growth but lacks FDA approval and clinical trial evidence.

Ritlecitinib effectively treats alopecia areata in patients 12 and older with fewer side effects.

Cancer survivors often experience worse skin problems from treatment than expected, and working with dermatologists could help improve their condition.

In June 2019, the stem cell research field saw major progress, including new clinical trials, FDA approvals, and industry collaborations.

Transdermal testosterone can improve sexual desire in postmenopausal women but lacks long-term safety data and is not FDA-approved for this use.

The FDA approved the first gene therapy for a blood disorder after overcoming early challenges and demonstrating patient benefits.

Minoxidil is the only FDA-approved treatment for female hair loss, with other potential treatments needing more research for effectiveness.

The FDA warned about safety issues with remdesivir and tofacitinib, finasteride is linked to suicidality, potent topical corticosteroids increase osteoporosis risk, henna can cause hemolysis in G6PD deficiency, chemotherapeutic agents can cause adverse reactions, drug interactions are common in cancer patients, ketamine can reduce at-risk drinking, high dose of anticholinergics increases dementia risk in Parkinson's patients, and prenatal exposure to second-generation antipsychotics increases pregnancy complications.

The FDA approved a new breast cancer treatment, found flu shots may reduce heart risks, questioned the safety of fast-tracked drug approvals, showed statins don't help with certain pneumonia, and approved a new dementia imaging agent.

New partnerships, clinical trials, and drug approvals marked progress in therapeutic delivery in July 2018.

Many treatments for hair loss lack proper testing and FDA approval, so their effectiveness is uncertain.

Exosome treatment for hair growth is promising but not FDA-approved and needs more research on safety and how it works.

Exosomes show promise in dermatology but need more research and FDA approval for clinical use.

Platelet-rich plasma therapy improves hair growth and health in androgenetic alopecia better than some FDA-approved treatments.

There are many treatments for common hair loss, but more trials are needed to decide which are best.

More men are using medication for benign prostatic hyperplasia, influenced by marketing and FDA approvals.

Coumarin derivatives show promise as anti-estrogenic agents for treating breast cancer, with some in clinical trials.

Mesotherapy lacks strong evidence for effectiveness and safety, and its ingredients are not FDA-approved for subcutaneous use.

Platelet-rich plasma can increase hair density and may help treat some skin conditions, but it's costly, not FDA-approved, and needs more research.